-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $400

Benzinga·07/22/2026 14:44:08
語音播報
JP Morgan analyst Jessica Fye maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $420 to $400.